Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

NCT04214418 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

27

Enrollment

OTHER

Sponsor class

Stopped Toxicity and Lack of Efficacy

Conditions

Gastrointestinal Cancer

Interventions

DRUG: Cobimetinib
DRUG: Hydroxychloroquine
DRUG: Atezolizumab

Sponsor

Columbia University

Collaborators

[object Object]